Oncotarget

Research Papers:

CMV70-3P miRNA contributes to the CMV mediated glioma stemness and represents a target for glioma experimental therapy

Ilya V. Ulasov, Natalya V. Kaverina, Dhimankrishna Ghosh, Marya A. Baryshnikova, Zaira G. Kadagidze, Apollon I. Karseladze, Anatoly Y. Baryshnikov and Charles S. Cobbs _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:25989-25999. https://doi.org/10.18632/oncotarget.11175

Metrics: PDF 926 views  |   HTML 1932 views  |   ?  


Abstract

Ilya V. Ulasov1,2,3, Natalya V. Kaverina3,4, Dhimankrishna Ghosh1, Marya A. Baryshnikova2,3, Zaira G. Kadagidze3, Apollon I. Karseladze3, Anatoly Y. Baryshnikov2,3, Charles S. Cobbs1

1Swedish Neuroscience Institute, Center for Advanced Brain Tumor Treatment, Seattle, WA, 98122, USA

2Institute of Experimental Diagnostics and Therapy of Tumors, N.N. Blokhin Russian Cancer Research Center, Moscow, 115478, Russia

3NN. Blokhin Cancer Research Center, RAMN, Moscow, 115478, Russia

4Current employment: Division of Nephrology, University of Washington, Seattle, 98109, WA, USA

Correspondence to:

Ilya V. Ulasov, email: Ilya.Ulasov@Swedish.org

Charles S. Cobbs, email: Charles.Cobbs@Swedish.org

Keywords: brain tumor, cytomegalovirus, glioma stem cells, miRNA

Received: November 17, 2015     Accepted: July 26, 2016     Published: August 10, 2016

ABSTRACT

Glioblastoma multiforme (GBM) is a rapidly progressive brain tumor with a median survival of 15–19 months. Therapeutic resistance and recurrence of the disease is attributed to cancer stem cells (CSC). Here, we report that CMV70-3P miRNA encoded by CMV increases GBM CSC stemness. Inhibition of CMV70-3P expression using oligo inhibitors significantly attenuated the ability of primary glioma cells to proliferate and form neurospheres. At the molecular level, we show that CM70-3P increases expression of cellular SOX2. Collectively, these findings indicate that CMV70-3P is a potential regulator of CMV- mediated glioma progression and cancer stemness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11175